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Abstract
Objective—To estimate and identify factors associated with incidence of all-cause end-stage 
renal disease (ESRD) among newly diagnosed systemic lupus erythematosus (SLE) patients.
Methods—Data from a national registry of treated ESRD were linked to data from a lupus 
registry of SLE patients who were newly diagnosed and living in Atlanta, Georgia, in 2002-2004 
(median follow-up, 7.8 years). Cumulative incidence and incidence rates (ESRD treatment 
initiations per 1000 patient-years) were calculated, and age- and race-adjusted Poisson models 
were used to calculate incidence rate ratios (IRRs).
Results—Among 344 newly diagnosed SLE patients, 29 initiated ESRD over 2603.8 years of 
follow-up. Incidence rates were 13.8 (95% CI, 9.4-20.3) and 3.3 (95% CI, 0.8-13.0) per 1000 
patient-years among black and white patients, respectively; corresponding 5-year cumulative 
incidence was 6.4% and 2.5%. Lupus nephritis documented prior to 2005, which occurred in 80% 
of those who progressed to ESRD, was the strongest risk factor for incident ESRD (IRR=6.7, 95% 
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CI, 2.7-16.8; incidence rate=27.6 per 1000 patient-years). Results suggested that patients who 
were black vs. white (IRR=3.9, 95% CI, 0.9-16.4) or <18 years (vs. ≥30 years) at diagnosis 
(IRR=2.1, 95% CI, 0.9-5.3) may be more likely to progress to ESRD, but incidence did not differ 
by sex or other characteristics.
Conclusion—Incidence of all-cause ESRD among patients with a recent diagnosis of SLE is 
high in Georgia. Interventions to decrease ESRD incidence among newly diagnosed SLE patients 
should target young and black patients as well as patients with lupus nephritis.
More than 5000 patients initiated treatment for end-stage renal disease (ESRD) attributed to 
systemic lupus erythematosus (SLE) in 2007-2011 (1). The population-based incidence of 
SLE-attributed ESRD has been estimated at 3-4 per million per year (2-5). Substantial 
disparities have been described in population incidence of SLE-attributed ESRD, by 
younger age (4-6), female sex (4), black race (2, 4-6), lower socioeconomic status (SES) (7, 
8), reduced access to care (9), and residence in the South (4, 6). However, there is little 
reliable information on the incidence of ESRD among those with SLE. Estimates of lupus 
nephritis (LN) incidence among SLE patients range widely, from 35% to 60% (10-14). 
Similarly, estimates of ESRD among those with existing LN range from 10% to 35% (15, 
16). The biases inherent in these estimates include survival bias (due to calculation of 
cumulative incidence rather than incidence rates) and misclassification (due to case 
definitions that often depend on administrative data to identify SLE and LN). In addition, 
combining estimates of LN incidence among those with SLE with estimates of ESRD 
incidence among those with LN—from different studies with varying follow-up times, 
population demographics, and sample sizes—could introduce even greater error and exclude 
ESRD cases not related to LN. Population-based ESRD incidence rate estimates among 
individuals with a validated diagnosis of SLE are important because ESRD remains the 
strongest risk factor for early mortality in the SLE population (17-20).
Estimates of the incidence rate of ESRD, as well as potential predictors of ESRD, among 
SLE patients are critical to guide treatment, screening, and management of this population. 
The Georgia Lupus Registry (GLR) (21, 22), which recently published estimates of 
population incidence of SLE in metropolitan Atlanta (23), offers a unique opportunity to 
estimate all-cause ESRD incidence among individuals with a new, validated diagnosis of 
SLE, free of much of the bias and variability of previous studies. The purpose of this study 
is to provide estimates of the incidence of ESRD using a population-based registry of newly 
diagnosed SLE patients in the southeastern United States and identify patient characteristics 
that might contribute to variation in ESRD incidence among SLE patients.
Patients and Methods
Data Sources and Study Population
Georgia Lupus Registry—The GLR is a population-based registry of validated SLE 
cases in a large (1.5 million) population with ~50% of individuals at high risk for SLE due 
to black race(14, 23-28). The primary aim of the GLR was to more accurately estimate the 
incidence and prevalence of SLE in 2002-2004 in Fulton and DeKalb Counties (Atlanta), 
Georgia (23). GLR methods are described in detail elsewhere (22, 23). Briefly, Emory 
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investigators served as designated agents of the Georgia Department of Public Health, who 
used its public health surveillance exemption to the HIPAA Privacy Rule (45 CFR parts 160 
and 164) to review medical records and capture protected health information without 
requiring patient consent [HIPAA 45 CFR 164.512(b)]. Potential SLE cases were identified 
from multiple sources, including hospitals; rheumatologists, dermatologists, and 
nephrologists; commercial and hospital-based laboratories; regional pathology laboratories; 
lupus research databases; and population databases, including the United States Renal Data 
System (USRDS), Veterans Affairs data, Medicaid claims data, and state mortality and 
hospital discharge data. The presence of diagnostic codes [International Classification of 
Diseases, 9th revision (ICD-9)] for SLE (710.0) and related conditions—including discoid 
lupus (695.4), other specified connective tissue disease (710.8), and other unspecified 
connective tissue disease (710.9)—in any of these sources flagged patients as potential SLE 
cases (22). All available medical records were fully abstracted for each potential case with 
residence in Fulton or DeKalb County in 2002-2004. Trained abstractors abstracted nearly 
250 data elements, including clinical data needed to validate the diagnosis of SLE [e.g., 
American College of Rheumatology (ACR) (29) and Systemic Lupus International 
collaborating Clinics (SLICC) (30) classification criteria], earliest date of physician-stated 
diagnosis of SLE in the medical record, demographics, residential address, and date of 
death. Data were abstracted from the earliest available medical record through 12/31/2004, 
when ascertainment and validation of incident cases for GLR concluded. Vital status was 
ascertained by periodic linkages of the GLR to the state mortality database and batch 
searches in the Social Security Death Index (last available date, 4/30/11). The project was 
reviewed and approved by the Emory University and Georgia Department of Public Health 
Institutional Review Boards.
United States Renal Data System—The USRDS provides an ongoing, integrated 
database for outcomes research on the treated U.S. ESRD population, who are Medicare-
eligible regardless of age or disability (1). We used the 2014 USRDS Standard Analytic 
Files, which contain data through 9/30/12 and originate primarily from the Centers for 
Medicare & Medicaid Services (CMS), to obtain date of initiation of ESRD treatment.
U.S. Census—Publicly available data on characteristics of U.S. residential neighborhoods, 
as defined by census tracts, were obtained from the 2000 U.S. Census (www.census.gov) via 
the Minnesota Population Center (www.nghis.org) (31). Aggregate census tract-level data 
on education and poverty were extracted.
Data linkage—Identifiers [Social Security number (SSN), date of birth, sex, first name, 
and surname] on incident SLE patients were sent to the USRDS to identify those who 
progressed to ESRD from diagnosis of SLE (2002-2004) to the last date of follow-up in the 
USRDS (9/30/12). Census data were spatially linked to the geocoded data from the GLR 
identifying the census tract associated with the first patient residential address recorded in 
Fulton or DeKalb County in 2002-2004. The GLR-USRDS data linkage was approved by 
the Emory Institutional Review Board.
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Study Population—Newly diagnosed SLE cases (n=345) were defined as those with an 
initial SLE diagnosis date from 1/1/02 through 12/31/04. For this study, SLE cases were 
defined by a combined case definition (23) to estimate population prevalence and incidence 
of SLE, as follows: (i) presence of ≥4 ACR criteria for classification of SLE (29) in the 
medical record (n=267); (ii) presence of 3 ACR criteria plus a treating, board-certified 
rheumatologist’s diagnosis of SLE (n=69); or (iii) <4 ACR criteria plus SLE kidney disease, 
as defined by a biopsy consistent with class II-VI LN (n=9) (32, 33).
Study Variables and Definitions
Incident ESRD—Incident ESRD was defined by a first ESRD treatment, for any attributed 
cause, on or after the date of SLE diagnosis (Figure 1).
Patient characteristics—The GLR included information on age, sex, race, and LN, 
defined as documentation of (i) urine abnormalities (documented at least twice; ≥500 mg 
protein in 24-hour urine, random urine protein ≥300 mg/dl, spot protein:creatinine ratio of 
≥0.5, or positive urine cellular casts), (ii) any renal biopsy consistent with LN classes II-VI 
(31), or (iii) documentation of LN by a treating rheumatologist or nephrologist. Because 
GLR data abstraction ended by 2005, LN could only be documented within a maximum of 3 
years from SLE diagnosis; thus, LN is hereafter referred to as early LN. Analyses by race 
were limited to black and white patients, due to low numbers of other races (Asian, n=11, 1 
event; missing, n=3, 0 events). We used the term “black” for consistency with the U.S. 
census classification (23). ESRD incidence by ethnicity was not reported due to low 
numbers (Hispanic, n=16, 1 event; missing ethnicity, n=10, 0 events). Individual SES was 
estimated by low-education and poor neighborhoods, defined as residential census tracts 
with greater than the median percentage of residents aged >25 without a high school degree 
or equivalent and households living below 100% of the federal poverty threshold, 
respectively.
Statistical Analysis
Patient characteristics were summarized for newly diagnosed SLE patients, overall and by 
ESRD status. All-cause ESRD incidence rates were calculated as the total number of 
patients initiating ESRD treatment over follow-up, divided by the sum of all patients’ 
contributed follow-up years. Follow-up time was defined as the time from date of SLE 
diagnosis to the time of death, ESRD, or last date of follow-up. For primary analyses, the 
last date of follow-up was 4/30/11, which is the last available date of death in GLR (Figure 
1), and SLE was defined by the combined case definition. Secondary incidence estimates 
used (i) incident SLE patients defined by ≥4 ACR criteria only and (ii) point prevalent 
patients (n=1488) with an existing diagnosis of SLE (combined case definition) and free of 
ESRD as of 12/31/04 (cumulative incidence only). Confidence intervals for rates were 
obtained by quadratic approximation based on the Poisson log-likelihood. Incidence rates 
were stratified by patient characteristics and incidence rate ratios (IRRs) and 95% 
confidence intervals (CIs) for the associations between patient characteristics were estimated 
with Poisson models. Stratified crude and adjusted incidence rates were calculated, and 
IRRs were adjusted for age group (<18 years, 18-30 years, and >30 years) and race (black 
and white). Clustering by census tract was minimal (n=86, 94, 48, 36, and 35 living in tracts 
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with 1, 2, 3, 4, and 5 patients, respectively) and neighborhood characteristics were assigned 
as individual-level variables. Stata v. 13 (StataCorp, College Station, TX) was used for all 
analyses. Statistical significance was assessed at α=0.05.
Results
Characteristics of Newly Diagnosed SLE Patients
Among the 345 Atlanta-area SLE patients newly diagnosed in 2002-2004, 31 (9.0%) were 
identified in the USRDS as having received treatment for all-cause ESRD through 9/30/12. 
For primary analyses, one patient was excluded for having initiated ESRD treatment prior to 
SLE diagnosis. Another patient who initiated ESRD treatment after 4/30/11 (last available 
date of vital status ascertainment for GLR) was included but the patient’s event was 
censored in primary analyses, leaving 29 ESRD events over 2603.8 patient-years of follow-
up among 344 newly diagnosed SLE patients without prior ESRD in 2002-2004 (Figure 1). 
Of these 344 patients, 299 (86.9%) had geocoded addresses that were linked successfully to 
2000 Census data. In GLR-USRDS linkage, 100% of the 29 patients with included ESRD 
events matched on Social Security Number and sex and >90% matched on date of birth and 
name.
Newly diagnosed SLE patients had a mean age of 36 and were 87% female and 76% black 
(Table 1). They lived in neighborhoods where medians of 13% had not completed high 
school and 11% lived below 100% the federal poverty threshold. About one-third of these 
patients had early LN (Table 1), diagnosed by 2005 (79% of those who progressed to 
ESRD), although this differed by race (20% and 39% of whites and blacks had early LN; 
P=0.001). Among those with LN and biopsy information (n=112), 66 (59%) had at least one 
kidney biopsy (53% and 60.0% of whites and blacks, respectively; P=0.8); only 7% had 
multiple kidney biopsies (13% and 6% of whites and blacks, respectively, P=0.3).
Those who progressed to ESRD were younger at SLE diagnosis and more likely to be black 
(vs. white) and to have greater numbers of ACR criteria (Table 1). Among those progressing 
to ESRD, 79% had early LN (documented before 2005), compared to only 30% of those 
who did not progress to ESRD (P<0.001; Table 1). There were no statistically significant 
differences in patient characteristics between those with and without early LN among those 
who progressed to ESRD (n=29). Of the 26 black SLE patients progressing to ESRD, 20 
(77%) had clinical evidence of early LN; while 16 (62%) had had at least one renal biopsy. 
In contrast, both white SLE patients who progressed to ESRD had early LN and at least one 
kidney biopsy in the medical record.
Incidence of ESRD among Newly Diagnosed SLE Patients
The overall crude incidence rate of all-cause ESRD in this Atlanta population with newly 
diagnosed SLE was 11.1 per 1000 patient-years (Table 2). Incidence rates were 13.8 and 3.3 
per 1000 patient-years among black and white patients, respectively (Table 3). Overall 
incidence was slightly higher (12.5 per 1000 patient-years) among those with SLE defined 
by ≥4 ACR criteria alone (Table 2). The 5-year cumulative incidence of ESRD among 
newly diagnosed SLE patients in our study was 5.2% (Table 2; 6.4% vs. 2.5% among black 
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vs. white patients). Over these 5 years, 15 (4.4%) died without an ESRD diagnosis. The 
median time to ESRD among those who progressed to ESRD by 4/30/11 was ~4 years 
(Table 2) among newly diagnosed SLE patients, and rates remained steady over follow-up in 
both blacks (Figure 2) and whites. Among 1488 point prevalent SLE patients (combined 
case definition) who were free of ESRD on 12/31/04, the 5-year cumulative incidence of 
ESRD was 5.2% (Table 2; 6.6% and 1.4% among black and white patients) and 16/1488 
(1.1%) had incident ESRD within 1 year (1.4% and 0.3% among black and white patients).
Overall ESRD incidence estimates in secondary analyses were similar. With ESRD follow-
up extended through 7/31/11, to include all patients who progressed to ESRD, regardless of 
missing death information after 4/30/11, the incidence rate among those with SLE by the 
combined case definition was 11.2 per 1000 patient years (cumulative incidence=5.2%). For 
those defined as having SLE by an intermediate definition (≥4 ACR criteria or 3 ACR 
criteria plus a treating rheumatologist diagnosis), the incidence rate was 11.1 per 1000 
patient-years (cumulative incidence=5.4%).
ESRD Incidence by Newly Diagnosed SLE Patient Characteristics
Those with early LN (diagnosed by 2005) had nearly 7-fold greater rates of ESRD compared 
to those with no LN diagnosis by 2005, with adjustment for age and race (Table 3). Pediatric 
(age <18 years) patients at SLE diagnosis were >2-fold more likely than older adults (≥30 
years) to progress to ESRD (Table 3). Male sex was not associated with ESRD incidence 
(Table 3). Blacks were nearly 4 times more likely than whites to progress to ESRD after 
adjustment for age (Table 3). Only the association with early LN was statistically 
significant, regardless of chosen referent group. Age- and race-adjusted incidence rates, 
omitted from Table 3 due to small sample sizes, did not differ substantially from the crude 
incidence rates presented in Table 3 (data not shown). SLE patients living in low-education 
and poor neighborhoods had modestly but non-statistically significantly higher rates of 
incident ESRD (Table 3).
Discussion
We have shown that, among urban Southeastern U.S. SLE patients, ESRD is a relatively 
common outcome. In a population-based registry of 344 newly diagnosed (2002-2004) 
Atlanta SLE patients, three of four of whom were black, the incidence rate of subsequent all-
cause ESRD was 11.1 per 1000 patient-years. Incidence rates were 13.8 and 3.3 per 1000 
patient-years among black and white patients, respectively. We estimated the overall 5-year 
cumulative incidence to be 5.2%, which is at least twice previous estimates from Taiwan, 
where 2.5% of newly diagnosed SLE patients developed ESRD over 6-8 years of follow-up 
(34), and Japan, where 3.1% of SLE patients diagnosed in 1971-1991 progressed to ESRD 
within 5 years (35). Both populations likely differ from the U.S. population and, 
particularly, this metropolitan Atlanta population, in terms of race—note that 5-year 
cumulative incidence was 6.4% among black SLE patients vs. only 2.5% among white SLE 
patients in our population—as well as environmental and healthcare system factors. Our 
study is, to our knowledge, the first to report an ESRD incidence rate among a population-
based registry of newly diagnosed U.S. SLE patients who were not identified and validated 
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by administrative data alone. Additionally, we were able to take mortality (4.4% of our 
incident SLE cohort over 5 years) into account by computing incidence rates.
Our results also point to associations of several patient characteristics with higher ESRD 
incidence among U.S. SLE patients. Early LN was associated with higher ESRD incidence, 
relative to not having this evidence of early renal disease (27.6 vs. 3.4 per 1000 patient-
years), and incidence remained nearly 7-fold higher after adjustment for age and race. 
Among black SLE patients who did have early LN and progressed to ESRD, 20% did not 
have evidence of a renal biopsy, suggesting that LN may not always be properly diagnosed, 
staged, and treated according to ACR guidelines for LN treatment (11), which recommend 
that all patients with signs of nephritis be biopsied and that all patients with Class III or IV 
LN be treated aggressively. This potential gap in the care of U.S. LN patients aligns with 
evidence from the Medicaid population: even among patients with a documented diagnosis 
of incident LN, only 34% and 56% of these patients were treated with immunosuppressants 
and renal-protective antihypertensive medications, respectively, to slow the progression of 
LN (36).
Despite early LN being the strongest risk factor for progression to ESRD that we examined, 
one in five SLE patients who progressed to ESRD had no early signs of LN in the medical 
record. Thus, other individual characteristics may be useful to providers and researchers in 
assessing ESRD risk among SLE patients who have not been screened for renal 
complications. We found that black and pediatric patients had nearly 4- and 2-fold higher 
ESRD incidence than white and adult patients. Although not statistically significant, our 
findings are consistent with other studies showing these characteristics to be associated with 
development and progression of LN and ESRD in the population (3-6, 15, 37-39).
Further, we showed steady incidence of ESRD among black patients over follow-up, 
suggesting many have rapid progression. Faster progression among blacks would contribute 
to disparities by providing a shorter window to identify kidney complications and intervene 
with aggressive treatments to prevent or delay ESRD. Social and behavioral factors, 
including those that influence access to care, early diagnosis, and appropriate treatment (e.g., 
institutional racism, differential availability of subspecialty care, trust in the healthcare 
system, and adherence) could contribute to this racial disparity. In a recent UK study, black 
race was not a predictor of poor SLE outcomes among those with equal access to healthcare 
(40). Although delays in care were actually less likely to occur among black vs. white 
patients with incident LN in the U.S. Medicaid population (36), additional health system and 
individual barriers for effective LN treatment among blacks such as differential treatment 
adherence (41) could potentially explain worse outcomes in this subpopulation. Other 
contributors to this disparity may be differentially inadequate treatment of comorbid 
hypertension and diabetes, which are common in SLE (42, 43) and associated ESRD (4) and 
represent the strongest risk factors for ESRD in the general population (1). Genetic factors 
may play a role as well: for example, the APOL1 gene, which is more frequent in U.S. 
blacks than whites, was recently shown to be associated with risk of ESRD among SLE 
patients in a case-control study (44).
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Among children, genetic and family history factors may play an even greater role in ESRD 
progression risk (45). In our study, crude incidence rates were ~20 per 1000 patient-years 
among children, more than twice the rate (<9 per 1000 patient-years) among adults aged ≥30 
years. However, even among children, sociodemographic factors may play a role: previous 
studies have shown that nearly 40% of children with SLE have LN (37), that female and 
non-white children with SLE in the Medicaid population are more likely to have LN (37), 
that half of children with ESRD due to SLE are on Medicaid insurance (6), and that black 
children with ESRD due to SLE have increased mortality relative to their white counterparts 
in the United States (6). Decreasing the incidence of ESRD in this pediatric population is of 
paramount importance, given additional, age-specific consequences of ESRD, such as 
decreased growth and school performance (46, 47).
Unlike previous studies in Okinawa (34) and the U.S. multiethnic PROFILE cohort (38), we 
found that male SLE patients were not at higher risk of ESRD. Our results may reflect 
differences across populations or simply chance findings due to low numbers of male SLE 
patients. Confirmation in other U.S. SLE cohorts is needed before male sex can be ruled out 
as a potential predictor of incident ESRD. Generally, we also found that neighborhood SES 
factors were not associated with ESRD incidence, although this does not preclude potential 
individual SES effects.
This study has several limitations. First, the sensitivity of the GLR SLE case-finding 
approach is unknown. However, the validity of the GLR methods to ascertain SLE cases 
was supported by results from the capture-recapture analyses, which showed that only 31 
incident cases with a validated diagnosis of SLE could have been missed (23). Second, race-
stratified estimates may be more appropriate than the overall estimates in generalizing to 
other U.S. SLE populations with different race/ethnicity distributions than Atlanta, where 
three-quarters of SLE patients were black and data on Hispanic and Asian SLE patients were 
lacking. Third, we had limited power to detect modest associations and could not account 
for potential neighborhood-level effects with multi-level modeling, due to small numbers of 
events and relatively short follow-up. Fourth, we lacked individual socioeconomic data. 
Fifth, the effects of potentially protective treatment, such as anti-malarials (48), could not be 
examined. Sixth, because prospective data capture was not within the scope of the GLR, 
detailed clinical data were not abstracted after 2004. Particularly for LN, we could not tease 
apart the potential effects of the presence vs. timing of LN on ESRD incidence. Finally, we 
were not able to capture any non-Medicare-eligible patients (e.g., undocumented residents) 
or any patients who moved out of the United States.
This study also has many strengths. Taking advantage of an innovative public health 
strategy that allowed us to link the GLR with the USRDS, we were able to estimate the first 
population-based estimates of ESRD incidence among individuals with a recent diagnosis of 
SLE in the U.S. Southeast. The GLR is one of five CDC National Lupus Registries, the first 
comprehensive population-based epidemiological study of lupus conducted in the United 
States (22, 23, 27). Case ascertainment was maximized by the use of multiple sources, and 
SLE diagnoses were validated by comprehensive clinical data collected from individual 
records, likely reflecting the full spectrum of SLE. We used a large, representative U.S. 
Southeastern metropolitan population, and all U.S. patients who were treated for ESRD in 
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were captured. In addition to the cumulative incidence, we calculated the incidence rate of 
ESRD, providing unbiased estimates that account for mortality and residential mobility 
within the United States. Thus, our findings overcome many methodological limitations that 
could lead to survival, migration, and selection biases in the estimates of ESRD incidence in 
SLE.
In conclusion, this study provides dependable all-cause ESRD incidence estimates in a high-
risk population of newly diagnosed SLE patients from the southeastern United States. 
Additionally, we described SLE populations (patients with early LN and, potentially, 
pediatric and black patients) who may benefit from earlier identification as higher-risk for 
ESRD, more aggressive treatment to prevent or delay ESRD, and targeted preventive and 
quality improvement research efforts. These estimates of the burden of ESRD among U.S. 
SLE patients inform future research aimed at increasing health care access among those with 
SLE, facilitating early diagnosis of kidney complications including LN, improving quality of 
SLE care related to kidney disease, and developing more effective treatments for kidney 
disease in SLE.
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• Using an innovative public health strategy that allowed us to link patient data 
from a SLE population-based registry with national end-stage renal disease data, 
we estimated, for the first time to our knowledge, the incidence of subsequent 
all-cause end-stage renal disease among a high-risk population of newly 
diagnosed SLE patients
• Among 344 metropolitan Atlanta patients diagnosed with SLE in 2002-2004, we 
found that the incidence of end-stage renal disease was high, with 5-year 
cumulative incidence of 6.4% vs. 2.5% and incidence rates of 13.8 vs. 3.3 per 
1000 patient-years among black vs. white patients
• Overcoming many of the biases inherent in previous estimates, via 
comprehensive SLE case ascertainment, complete capture of all U.S. patients 
who were treated for end-stage renal disease, and incorporation of available 
mortality information, these incidence estimates are critical to guide treatment, 
screening, and management of SLE
• The risk for end-stage renal disease is higher in SLE patients with newly 
diagnosed patients with lupus nephritis and, potentially, those who are black or 
pediatric; these populations may benefit from earlier diagnosis of kidney 
complications and more aggressive treatment to prevent or delay end-stage renal 
disease
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Examples of included and excluded end-stage renal disease (ESRD) events and follow-up 
time in the estimation of ESRD incidence among newly diagnosed (2002-2004) SLE 
patients in the Georgia Lupus Registry. End of death follow-up, 4/30/11; end of ESRD 
follow-up, 9/30/12. Of a total of 345 patients with 31 events in our data, 1 patient had a 
censored ESRD event after 4/30/11 (A) and 1 patient was excluded due to ESRD prior to 
SLE diagnosis (B), leaving 344 patients with 29 events over 2603.8 patient-years of follow-
up for the primary incidence estimates.
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Cumulative ESRD incidence among 251 black systemic lupus erythematosus patients 
diagnosed in Fulton and DeKalb Counties, Georgia, in 2002-2004. Note that cumulative 
incidence among whites is not shown due to small numbers of events (n=2).
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Table 1
Characteristics of newly diagnosed (2002-2004) SLE patientsa in the Georgia Lupus Registry, overall and by 
all-cause end-stage renal disease status through 4/30/11
Overall
(n=344)
ESRD status as of 4/30/11b
Characteristic N Yes (n=29) No (n=315) P c
Age at diagnosis of SLE,
mean (SD)
344 36.4 (16.4) 31.4 (17.7) 36.9 (16.2) 0.08
Sex, % 344 >0.9
 Male 45 (13.1%) 3 (10.3%) 42 (13.3%)
 Female 299 (86.9%) 26 (89.7%) 273 (86.7%)
Race,d % 330 0.04
 White 79 (23.9%) 2 (7.1%) 77 (25.5%)
 Black 251 (76.1%) 26 (92.9%) 225 (74.5%)


















Early lupus nephritis, % 344 <0.001
 No 225 (65.4%) 6 (20.7%) 219 (69.5%)
 Yes 119 (34.6%) 23 (79.3%) 96 (30.5%)
No. of ACR criteria, % 344
 ≤3 78 (22.7%) 74 (23.5%) 4 (13.8%) 0.03
 4 121 (35.2%) 115 (36.5%) 6 (20.7%)
 ≥5 145 (42.2%) 126 (40.0%) 19 (65.5%)
ESRD, end-stage renal disease; SLE, systemic lupus erythematosus; IQR, inter-quartile range; HS, high school. Early lupus nephritis was defined 
by urine or biopsy evidence or treatment rheumatologist or nephrologist documentation of lupus nephritis in the medical record, by 2005. Poor was 
defined as living below 100% federal poverty threshold.
a
By combined case definition: ≥4 ACR criteria, 3 ACR criteria plus treating rheumatologist’s diagnosis, or renal involvement as indicated by 
biopsy consistent with class II-VI lupus nephritis or ESRD requiring dialysis or renal transplantation.
b
Last date of death follow-up in the Georgia Lupus Registry. A total of 30 patients initiated ESRD treatment between date of SLE diagnosis and 
9/30/12, the last date of ESRD follow-up.
c
By Fisher’s exact test or Wilcoxon rank test across ESRD status.
d
Restricted to white and black patients only, due to small numbers of patients of other races (Asian, n=11, 1 event; missing race, n=2, 0 events).
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Table 2



























344 29 2603.8 4.1 (2.0-5.9) 11.1 (7.7-16.0) 5.2
Incident SLE by≥4




1488 95 --- 2.6 (1.6-4.6) --- 5.2
ACR, American College of Rheumatology; ESRD, end-stage renal disease; IQR, interquartile range; SLE, systemic lupus erythematosus.
a
Last date of death follow-up in the Georgia Lupus Registry. A total of 30 patients initiated ESRD treatment between date of SLE diagnosis and 
9/30/12, the last date of ESRD follow-up.
bAmong those who progress to ESRD by 4/30/11.
c
Representing 18, 16, and 78 ESRD events within 5 years for the three cohorts listed.
dCombined case definition, ≥4 ACR criteria, 3 ACR criteria plus treating rheumatologist’s diagnosis, or renal involvement as indicated by biopsy 
consistent with class II-VI lupus nephritis or ESRD requiring dialysis or renal transplantation.
e
Point prevalent cohort of patients in the GLR alive with an existing diagnosis of SLE (primary combined case definition) and free of ESRD on 
12/31/04. Because patients who died with SLE prior to 12/31/04 were at risk for ESRD, patient-years and incidence rates were not calculated for 
this cohort.
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Table 3
All-cause end-stage renal disease incidence among newly diagnosed (2002-2004) SLEa patients, by patient 













Age at SLE diagnosis
 <18 7/344.2 20.3 (9.7-42.7) 2.14 (0.86-5.33)
 18-30 8/636.9 12.6 (6.3-25.1) 1.19 (0.48-2.96)
 >30 14/1622.7 8.6 (5.1-14.6) 1.00 (ref)
Sex
 Female 26/2260.0 11.5 (7.8-16.9) 1.00 (ref)
 Male 3/343.8 8.7 (2.8-27.0) 0.77 (0.23-2.56)
Race
 White 2/615.1 3.3 (0.8-13.0) 1.00 (ref.)
 Black 26/1877.2 13.8 (9.4-20.3) 3.85 (0.91-16.35)
Low educationd
 No 10/1143.2 8.7 (4.7-16.3) 1.00 (ref)
 Yes 18/1118.5 16.1 (10.1-25.5) 1.24 (0.55-2.80)
Poord
 No 12/1136.7 10.6 (6.0-18.6) 1.00 (ref)
 Yes 16/1124.9 14.2 (8.7-23.2) 1.14 (0.52-2.50)
Early lupus nephritis
 No 6/1753.0 3.4 (1.5-7.5) 1.00 (ref.)
 Yes 23/850.8 27.6 (18.2-41.5) 6.72 (2.69-16.82)
No. of ACR criteria, %
 4 6/930.7 6.4 (2.9-14.3) 1.00 (ref.)
 ≤3 4/596.1 6.7 (2.5-17.9) 1.01 (0.38-3.60)
 ≥5 19/1077.0 17.5 (11.3-27.7) 2.24 (0.88-5.71)
CI, confidence interval; ESRD, end-stage renal disease; SLE systemic lupus erythematosus. Early lupus nephritis defined by urine or biopsy 
evidence or treatment rheumatologist or nephrologist documentation of LN in the medical record, within 3 years of SLE diagnosis. Early lupus 
nephritis was defined by urine or biopsy evidence or treatment rheumatologist or nephrologist documentation of lupus nephritis in the medical 
record, by 2005.
a
By combined case definition: ≥4 ACR criteria, 3 ACR criteria plus treating rheumatologist’s diagnosis, or renal involvement as indicated by 
biopsy consistent with class II-VI lupus nephritis or ESRD requiring dialysis or renal transplantation.
b
Last date of death follow-up in the Georgia Lupus Registry. A total of 30 patients initiated ESRD treatment between date of SLE diagnosis and 
9/30/12, the last date of ESRD follow-up.
cAdjustment for age group (<18, 18-30, >30 years) and race (black and white only).
d
Defined as living in a census tract with above (yes)/below (no) median values presented in Table 1: % high school dropouts, 13.2%; and % living 
below 100% federal poverty threshold, 11.1%.
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